Ngai Roland Y, Marbou Wiliane J T, Mbaveng Armelle T, Kuete Victor
Department of Biochemistry, Faculty of Science, University of Dschang, Cameroon.
Can J Infect Dis Med Microbiol. 2024 Oct 25;2024:3383995. doi: 10.1155/2024/3383995. eCollection 2024.
Malarial and bacterial coinfections in low-income countries are a serious cause of morbidity and mortality, necessitating coadministration of antibiotics and antimalarials. This study investigated the relationship between malaria infection and bacterial drug resistance in malaria and nonmalaria patients on consultation at the Dschang Regional Hospital. A follow-up study was carried out from October 2020 to December 2021 on 127 malaria and 174 nonmalaria patients having enteric infections. Clinical and haematological parameters were measured using standard methods. CD4 and CD8 cells were determined using flow cytometry. Enteric bacteria pathogens were isolated from stool, and antimicrobial and antimalarial profiles were determined using agar diffusion and microdilution methods, respectively. Significant reduction of RBCs, WBCs, CD4, CD8, granulocytes, monocytes and platelets was seen in coinfected patients compared to monoinfected participants ( ≤ 0.0491). was the main pathogenic bacteria isolated from the digestive tract of coinfected patients (40.63%) and monoinfected patients (59.37%). showed a high level of resistance to AMX (57.69%) and CDA (61.54%) in coinfected patients compared to 55.26% and 41.67%, respectively, in monoinfected patients. Quinine (53[50.00%]; 6[42.86%]) presented a minimal inhibitory concentration (MIC) of 32 μg/mL on the bacteria isolates from coinfected and monoinfected patients, respectively, while Artemether 89 (83.96%), Maloxine 5 (3.94%) and Surquina 250 (39.37%) presented a MIC of 64 μg/mL on bacterial isolates of coinfected and monoinfected patients. showed high resistance against AKI (45.93%), AMX (43.75%) and ERY (59.37%) in malaria patients who were under antimalarial drugs compared to malaria patients who were not under malaria drugs (29.68%, 34.37% and 32.81%, respectively). This study highlights that antimalarial drugs might certainly have an influence on the acquisition and emergence of bacterial resistance in the case of malaria bacterial coinfection, and therefore, adequate management and planning effective control programmes might certainly go a long way to reduce the rate of morbidity and mortality.
低收入国家的疟疾与细菌合并感染是发病和死亡的一个严重原因，因此有必要同时使用抗生素和抗疟药。本研究调查了在雅温得地区医院就诊的疟疾患者和非疟疾患者中，疟疾感染与细菌耐药性之间的关系。2020年10月至2021年12月，对127名疟疾患者和174名患有肠道感染的非疟疾患者进行了一项随访研究。使用标准方法测量临床和血液学参数。使用流式细胞术测定CD4和CD8细胞。从粪便中分离出肠道细菌病原体，分别使用琼脂扩散法和微量稀释法测定抗菌和抗疟谱。与单一感染的参与者相比，合并感染的患者红细胞、白细胞、CD4、CD8、粒细胞、单核细胞和血小板显著减少（≤0.0491）。 是从合并感染患者（40.63%）和单一感染患者（59.37%）的消化道中分离出的主要病原菌。与单一感染患者中分别为55.26%和41.67%相比，合并感染患者中 对阿莫西林（AMX，57.69%）和头孢地尼（CDA，61.54%）表现出较高水平的耐药性。奎宁（合并感染患者中53例[50.00%]；单一感染患者中6例[42.86%]）对合并感染和单一感染患者的细菌分离株的最低抑菌浓度（MIC）分别为32μg/mL，而蒿甲醚89例（83.96%）、咯萘啶5例（3.94%）和磺胺多辛250例（39.37%）对合并感染和单一感染患者的细菌分离株的MIC为64μg/mL。与未使用抗疟药的疟疾患者（分别为29.68%、34.37%和32.81%）相比，正在使用抗疟药的疟疾患者中 对氨基糖苷类（AKI，45.93%）、阿莫西林（AMX，43.75%）和红霉素（ERY，59.37%）表现出较高的耐药性。本研究强调，在疟疾与细菌合并感染的情况下，抗疟药可能确实会对细菌耐药性的获得和出现产生影响，因此，进行适当的管理并制定有效的控制方案对于降低发病率和死亡率可能大有帮助。
